The field of incretin-based metabolic research has undergone a dramatic acceleration in recent years, driven by the development of peptide compounds that target not just one but multiple incretin and related receptor systems simultaneously. From the single-receptor GLP-1 agonist semaglutide to the dual-receptor agonist tirzepatide and the triple-receptor agonist retatrutide, each successive generation of metabolic peptides has expanded the scope of receptor engagement and produced increasingly robust effects in published clinical research. This article provides a comparative overview of these three landmark compounds, examining their mechanisms, structural innovations, clinical research data, and the scientific questions that remain.
The Incretin System: A Foundation for Comparison
The incretin system comprises gut-derived hormones that are released in response to nutrient ingestion and potentiate glucose-dependent insulin secretion from pancreatic beta cells. The two primary incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP, formerly known as gastric inhibitory polypeptide). Together, these hormones account for approximately 50 to 70% of postprandial insulin secretion, a phenomenon known as the incretin effect.
GLP-1, secreted by intestinal L-cells, activates the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in the pancreas, brain, heart, gastrointestinal tract, and other tissues. GLP-1R activation promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system signaling. GIP, secreted by intestinal K-cells, activates the GIP receptor (GIPR), which shares approximately 40% sequence homology with GLP-1R and is expressed in pancreatic beta cells, adipose tissue, bone, and brain. GIP signaling promotes insulin secretion and plays roles in lipid metabolism and bone turnover.
A third receptor system, the glucagon receptor (GCGR), has emerged as an additional target in metabolic research. Glucagon, produced by pancreatic alpha cells, activates GCGR to promote hepatic glucose production, lipolysis, thermogenesis, and amino acid catabolism. While glucagon has traditionally been viewed as a counter-regulatory hormone opposing insulin's actions, research has revealed that controlled glucagon receptor agonism can enhance energy expenditure and fat oxidation, providing a metabolic complement to GLP-1-mediated appetite suppression.
Semaglutide: The Single-Receptor Benchmark
Semaglutide is a selective GLP-1 receptor agonist and serves as the benchmark against which newer multi-receptor agonists are compared. As a modified analog of human GLP-1(7-37) with 94% sequence homology to the native peptide, semaglutide achieves its extended half-life of approximately 165 hours through an alpha-aminoisobutyric acid substitution at position 8 (conferring DPP-4 resistance) and a C-18 fatty diacid chain attached at position 26 (promoting albumin binding).
The clinical research program for semaglutide is among the most extensive for any peptide compound. The SUSTAIN program established its metabolic profile in type 2 diabetes research, while the STEP program extended investigations to subjects with obesity. The STEP 1 trial, published in the New England Journal of Medicine, reported mean weight reductions of approximately 14.9% from baseline with semaglutide 2.4 mg weekly over 68 weeks, establishing a new benchmark for pharmacological weight management research. The SELECT cardiovascular outcomes trial further demonstrated significant reductions in major adverse cardiovascular events, expanding the research interest in GLP-1 receptor pharmacology beyond metabolic endpoints.
Semaglutide's mechanism is entirely GLP-1R-mediated, meaning its metabolic effects are driven by a single receptor pathway. While this single-receptor approach has produced substantial clinical effects, the inherent limitation is that it does not engage the complementary metabolic pathways accessible through GIP or glucagon receptor signaling. This observation provided the scientific rationale for developing multi-receptor agonists.
Tirzepatide: Dual GLP-1/GIP Receptor Agonism
Tirzepatide represents a fundamental advance in metabolic peptide design as the first approved dual GLP-1/GIP receptor agonist. Developed by Eli Lilly, tirzepatide is a 39-amino acid synthetic peptide based on the native GIP sequence, engineered to activate both the GIP receptor and the GLP-1 receptor. This dual-receptor engagement was achieved through careful molecular engineering: the native GIP(1-39) backbone provides high-affinity GIPR binding, while specific amino acid modifications at multiple positions introduce GLP-1R agonist activity into the same molecule.
The structural design of tirzepatide incorporates several innovations. A C-20 fatty diacid moiety attached via a linker at position 20 promotes albumin binding and extends the half-life to approximately 5 days, enabling once-weekly administration. The Aib substitution at position 2 confers resistance to DPP-4 degradation, while multiple amino acid substitutions throughout the sequence optimize the balance of GLP-1R and GIPR binding affinities. Published receptor binding studies have characterized tirzepatide as having approximately 5-fold selectivity for GIPR over GLP-1R, though it functions as a full agonist at both receptors.
The SURPASS clinical research program for tirzepatide demonstrated metabolic effects that exceeded those observed with semaglutide in head-to-head comparisons. The SURPASS-2 trial, published in the New England Journal of Medicine, directly compared tirzepatide (5 mg, 10 mg, and 15 mg) to semaglutide 1 mg in subjects with type 2 diabetes. All three tirzepatide doses produced significantly greater reductions in HbA1c and body weight compared to semaglutide. At the highest dose (15 mg), tirzepatide produced mean weight reductions of approximately 12.4% compared to 6.2% for semaglutide 1 mg over 40 weeks.
The SURMOUNT program extended tirzepatide research to subjects with obesity. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported mean weight reductions of approximately 20.9% with tirzepatide 15 mg over 72 weeks, a magnitude of weight loss previously achievable only through surgical intervention. These results represented a significant advance over the semaglutide STEP data and generated substantial interest in the added value of GIP receptor co-agonism.
The contribution of GIPR agonism to tirzepatide's enhanced efficacy remains an active area of investigation. While GIP was historically considered an obesogenic hormone due to its effects on fat deposition, recent research has revealed that chronic GIPR agonism at pharmacological levels may paradoxically reduce body weight through mechanisms involving improved adipose tissue insulin sensitivity, enhanced lipid buffering capacity, and central nervous system effects that complement GLP-1R-mediated appetite suppression. Published preclinical studies suggest that GIP signaling in the brain may enhance the satiety signals generated by GLP-1R activation, producing a more robust anorectic effect than GLP-1R agonism alone.
Retatrutide: Triple GLP-1/GIP/Glucagon Receptor Agonism
Retatrutide (LY3437943), also developed by Eli Lilly, extends the multi-receptor agonist concept to its current frontier by engaging three receptor systems simultaneously: GLP-1R, GIPR, and GCGR. This triple-agonist approach adds glucagon receptor engagement to the dual GLP-1/GIP agonism of tirzepatide, incorporating the thermogenic and lipolytic effects of glucagon signaling into the metabolic mechanism of action.
Structurally, retatrutide is a 39-amino acid peptide engineered to activate all three target receptors from a single molecular scaffold. The compound incorporates a C-20 fatty diacid for albumin binding and extended half-life, similar to tirzepatide. Published receptor binding data characterize retatrutide as a full agonist at GIPR and GLP-1R with partial agonist activity at GCGR, a deliberate design choice that provides the metabolic benefits of glucagon signaling while mitigating the hyperglycemic risk associated with full glucagon receptor activation.
The Phase 2 clinical research data for retatrutide, published in the New England Journal of Medicine in 2023, reported the largest weight reductions observed for any pharmacological agent to date. Over 48 weeks, the highest dose group (12 mg) achieved mean weight reductions of approximately 24.2% from baseline, with 26% of participants achieving weight loss of 30% or more. These findings exceeded the results observed with both semaglutide and tirzepatide at comparable time points, suggesting that the addition of glucagon receptor agonism provides meaningful incremental metabolic benefit.
The mechanistic contribution of glucagon receptor agonism to retatrutide's enhanced efficacy is attributed primarily to increased energy expenditure through hepatic and adipose tissue thermogenesis. Published preclinical studies have demonstrated that GCGR activation increases resting metabolic rate through the activation of thermogenic pathways in brown and beige adipose tissue, promotion of hepatic fatty acid oxidation, and upregulation of fibroblast growth factor 21 (FGF21) secretion. By combining this expenditure-enhancing effect with the appetite-suppressive actions of GLP-1R and GIPR agonism, retatrutide addresses both sides of the energy balance equation simultaneously.
Structural and Mechanistic Comparison
Comparing these three compounds reveals a clear evolutionary trajectory in metabolic peptide design. Semaglutide, as a single-receptor agonist, achieves its effects entirely through GLP-1R-mediated appetite suppression, glucagon suppression, and delayed gastric emptying. Tirzepatide adds GIPR co-agonism, which appears to enhance the anorectic signal, improve adipose tissue metabolism, and potentially improve tolerability through mechanisms that are still being elucidated. Retatrutide further adds GCGR partial agonism, incorporating thermogenic energy expenditure into the mechanism profile.
From a molecular perspective, the progression from single to triple agonism represents an increasingly complex engineering challenge. Each additional receptor target introduces new constraints on the peptide sequence, as the molecule must maintain appropriate binding affinity and agonist activity at all target receptors while preserving adequate pharmacokinetic properties. The successful development of tirzepatide and retatrutide demonstrates that these engineering challenges can be overcome through systematic structure-activity relationship optimization guided by high-throughput receptor binding and functional assays.
Research Considerations and Future Directions
Researchers comparing these compounds should note several important considerations. First, the published clinical data for each compound reflect different study designs, populations, dose levels, and treatment durations, making direct cross-study comparisons inherently limited. The SURPASS-2 head-to-head comparison of tirzepatide versus semaglutide provides the strongest comparative data, though it compared tirzepatide at multiple doses against semaglutide at only 1 mg (not the higher 2.4 mg dose used in the STEP program). No head-to-head trials comparing all three compounds at their respective optimal doses have been published.
Second, the contribution of each receptor to the overall metabolic effect in multi-receptor agonists is difficult to isolate. Retatrutide's superior weight loss compared to tirzepatide could be attributed to GCGR agonism, but it could also reflect differences in GLP-1R or GIPR agonist potency, pharmacokinetic properties, or other structural factors. Controlled studies using selective receptor antagonists or receptor-specific mutations will be necessary to definitively parse the contribution of each target.
The rapid evolution from single to dual to triple agonism raises the broader question of whether additional receptor targets will yield further incremental benefit or whether a point of diminishing returns will be reached. Published preclinical studies have begun exploring even more complex multi-agonist molecules, but the trajectory from laboratory to clinical validation is long and uncertain. For the foreseeable future, semaglutide, tirzepatide, and retatrutide will likely remain the primary reference compounds in metabolic peptide research, each representing a distinct and informative approach to modulating incretin and related signaling pathways.
--- *Disclaimer: All compounds referenced in this article are sold for in-vitro research and educational purposes only. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.*About the Author
Research Analyst, PEPCELL Sciences
Dr. James Park earned his Ph.D. in Pharmacology from Johns Hopkins University, where his dissertation focused on GLP-1 receptor agonist mechanisms. He brings 10 years of pharmaceutical industry experience, including roles at Merck and Regeneron, to his analysis of peptide research trends and quality assurance protocols at PEPCELL Sciences.